Stephen Revell, MD, MBA has been on the cutting edge of international drug safety and pharmacovigilance for over 15 years. He has extensive experience in clinical and post marketing drug safety and has been an invited speaker at numerous drug safety courses and has presented at many scientific meetings. Dr Revell has had experience with both product withdrawal and product suspension and in this context has interacted with Regulatory Authorities in both the EU and US. He was an early adopter of the PSUR as a medium of providing safety information to the FDA. He has initiated and managed drug safety monitoring boards for multiple products in various therapeutic areas. In addition, his achievements include developing adverse event tracking systems, training courses, analysis of safety signals, review of individual safety report, and preparation of the safety sections for NDA submissions. He has authored and co-authored more than 25 publications, including multiple analyses of identified safety signals.

Dr Revell has held senior global executive positions in pharmacovigilance, medical affairs, and clinical research with Hoffmann-La Roche (Switzerland), Alza, Biogen Idec and Acadia Pharmaceuticals, working both in Europe and the US. This experience has provided him with insight into both large pharma and small biotech working environments.

Dr Revell received his medical degree from University of Rhodesia (currently University of Zimbabwe) and his MBA from the Open University (UK). He had post graduate training in both Anesthesiology and Pediatrics. Prior to joining the pharmaceutical industry he was a lecturer in the department of Pediatrics at the University of Cambridge. Dr Revell maintains his medical license in the UK. He is a dual UK/US citizen. Dr Revell resides on the West Coast of the US.